Patents by Inventor Jean Mesens

Jean Mesens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 7547452
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: June 16, 2009
    Assignees: Alkermes, Inc., Janssen Pharmaceutica, N.V
    Inventors: Thomas J. Atkins, Michael E. Rickey, Jean Mesens
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Publication number: 20080069885
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release and a duration of action of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
    Type: Application
    Filed: July 13, 2007
    Publication date: March 20, 2008
    Applicants: Alkermes, Inc., Janssen Pharmaceutica, N.V.
    Inventors: Jean Mesens, Michael Rickey, Thomas Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Publication number: 20080063721
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
    Type: Application
    Filed: July 13, 2007
    Publication date: March 13, 2008
    Applicants: Alkermes, Inc., Janssen Pharmaceutica, N.V.
    Inventors: Jean Mesens, Michael Rickey, Thomas Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 7118763
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: October 10, 2006
    Assignees: Alkermes Controlled Therapeutics, Inc. II, Janssen Pharmaceutica
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Publication number: 20060182810
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Application
    Filed: March 2, 2006
    Publication date: August 17, 2006
    Applicants: Janssen Pharmaceutica, N.V., Alkermes Controlled Therapeutics Inc. II
    Inventors: Jean Mesens, Michael Rickey, Thomas Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Publication number: 20050025828
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Application
    Filed: August 18, 2004
    Publication date: February 3, 2005
    Applicants: Alkermes Controlled Therapeutics Inc. II, Janssen Pharmaceutica
    Inventors: Jean Mesens, Michael Rickey, Thomas Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 6803055
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: October 12, 2004
    Assignees: Alkermas Controlled Therapeutics Inc. II, Janssen Pharmaceutica
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Publication number: 20030165571
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Application
    Filed: February 6, 2003
    Publication date: September 4, 2003
    Applicant: Alkermes Controlled Therapeutics Inc. II
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 6544559
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: April 8, 2003
    Assignees: Alkermes Controlled Therapeutics Inc. II, Janssen Parmaceutica
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Publication number: 20020098233
    Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.
    Type: Application
    Filed: January 29, 2002
    Publication date: July 25, 2002
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 6368632
    Abstract: Method of treating warm blooded animals suffering from psychotic disorders. The method includes administering a pharmaceutically effective amount of sustained-release microparticles that include risperidone, or a pharmaceutically acceptable acid addition salt thereof, and a biodegradable and biocompatible polymeric matrix.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: April 9, 2002
    Assignees: Janssen Pharmaceutica, Alkermes Controlled Therapeutics Inc. II
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 6110921
    Abstract: The invention relates to a method of treating psychotic disorders comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: August 29, 2000
    Assignees: Alkermes Controlled Therapeutics Inc. II, Janssen Pharmaceutica
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 5965168
    Abstract: The invention relates to a pharmaceutical composition comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, within a polymeric matrix.
    Type: Grant
    Filed: January 12, 1998
    Date of Patent: October 12, 1999
    Assignees: Alkermes Controlled Therapeutics, Inc. II, Janssen Pharmaceutica
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
    Patent number: 5792477
    Abstract: A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymeric encapsulating binder, and an active agent having limited water solubility dissolved or dispersed in a solvent. An aqueous second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are separated. The discontinuous first phase is washed with water, or an aqueous solution of water and a solvent for residual solvent in the first phase, to reduce the level of residual solvent in the microparticles to less than about 2% by weight of the microparticles. Also disclosed are a microencapsulated drug prepared by the method for preparing biodegradable, biocompatible microparticles, and a pharmaceutical composition that includes biodegradable and biocompatible microparticles in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: August 11, 1998
    Assignees: Alkermes Controlled Therapeutics, Inc. II, Janssen Pharmaceutica
    Inventors: Michael E. Rickey, J. Michael Ramstack, Danny H. Lewis, Jean Mesens
  • Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1,2-benzisothiazoles
    Patent number: 5770231
    Abstract: The instant invention is related to a sustained-release microparticle produced by dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: June 23, 1998
    Assignees: Alkermes Controlled Therapeutics, Inc. II, Janssen Pharmaceutica
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
    Patent number: 5688801
    Abstract: A pharmaceutical composition comprising a biodegradable and biocompatible composition comprising a 1,2 benzazole within a polymeric matrix. The 1,2 benzazole composition, pharmaceutically acceptable acid addition salts thereof, are potent antagonists of a series of neurotransmitters, particularly serotonin and dopamine. A method of inhibiting both serotonergic overactivity and dopaminergic overstimulation in animals is provided by administration of a biodegradable and biocompatible microparticle composition comprising a 1,2 benzazole or a pharmaceutically acceptable acid addition salt thereof. A method of treating warm blooded animals suffering from psychotic disorders, and a method of preparing the biodegradable and biocompatible composition are also described.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: November 18, 1997
    Assignees: Janssen Pharmaceutica, Alkermes Controlled Therapeutics Inc. II
    Inventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
  • Etomidate-containing compositions
    Patent number: 4289783
    Abstract: Improved etomidate-containing compositions for intravenous administration comprising an infusion liquid to which has been added a relatively concentrated solution of an addition salt of etomidate in an ethanolic medium.
    Type: Grant
    Filed: January 16, 1980
    Date of Patent: September 15, 1981
    Assignee: Janssen Pharmaceutica, N.V.
    Inventor: Jean Mesens
  • Fluspirilene-containing compositions
    Patent number: 4213963
    Abstract: Improved fluspirilene-containing compositions for intramuscular administration and a method of preparing the same.
    Type: Grant
    Filed: December 14, 1978
    Date of Patent: July 22, 1980
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jean Mesens, Victor Haagen